Correct usage, dosage and precautions of Sotolaxib

Sotorasib (AMG510, Sotorasib) is a targeted drug targeting KRAS G12C mutations. It is mainly used to treat unresectable or metastatic KRAS G12C mutated non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). It reduces tumor proliferation and spread by specifically inhibiting the abnormal signaling pathways produced by KRAS G12C mutations.

In terms of usage and dosage, for the treatmentof locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutations, the recommended dose is 960mg (three 320mg tablets, four 240mg tablets or eight 120mg tablets taken orally daily), once a day. The taking time does not need to be strictly regulated, but it is recommended that patients take the medicine regularly every day until the disease worsens or unacceptable toxic reactions occur.

When sotoracib is given in combination with Panitumumab, the recommended dose for the treatment of patients with metastatic colorectal cancer (mCRC) is also 960 mg once daily. Patients should take their first dose of sotoraxib before starting an infusion of panitumumab. Combination therapy could help enhance the effectiveness of treatments for KRAS G12C mutant cancers, especially in patients who are resistant to conventional treatments.

As for the way of taking the medicine, sotoraxib is an oral medicine. Patients need to follow the doctor's instructions and choose the most appropriate dosage and administration method according to actual needs. If patients encounter difficulties in swallowing or other problems, they should communicate with their doctor in time to find an appropriate treatment method. It is worth noting that during long-term medication, patients must regularly undergo routine blood tests, liver and kidney function and other routine tests to monitor the safety of the medication and ensure maximum treatment effect.

Patients need to pay attention to some special considerations when using sotoraxib. First, patients should avoid concurrent use with certain drugs, such as strong CYP3A4 inducers, as these drugs may affect the metabolism of sotoraxib and reduce its efficacy. Secondly, when using this drug, patients may experience some adverse reactions, such as abnormal liver function, rash, gastrointestinal discomfort, etc. Therefore, regular physical examination and follow-up are very important.

Reference materials:https://www.lumakras.com/